




The 3rd Microbiome R&D and Business Collaboration Forum: USA

COLLABORATIONS & INVESTMENT IN MICROBIOTA RESEARCH, PROBIOTICS, HEALTH & DISEASE

Global Engage is pleased to announce our 3rd Microbiome R&D and Business Collaboration Forum: USA which will be held on 10-11 September in San Diego, CA, USA.

The field of metagenomics has allowed researchers to delve into the diversity of the body's microbiota with findings that the microbiome is a home for diversity, natural immunity, metabolism, behavioural traits, and plays an instrumental role in health and disease. With large-scale collaborative projects underway and sequencing data placed in the public domain, there is a rich source of information for researchers and companies looking for opportunities in this exciting field. With increasing signs that our microbiome may be the key not only for curative but preventative medicine, efforts are focusing on increasing investment opportunities, clinical trials and innovative research in this area. With an increasing focus on healthy living and a therapeutics market that is expected to grow to \$1.2 trillion by 2016, microbial research can be developed in order to provide preventative treatments, cures, therapies and supplements for a worldwide audience in demand.

Attracting over 200 attendees, the forum will build upon our successful American meeting last year and our popular sister European and Asian meetings to explore the interface between our evolving cultures, technologies and our microbiome through a series of interactive presentations with leading academics and industry experts, panel discussions with business leaders, investors and venture capitalists and an exhibition area allowing solution providers to showcase their products and services.

Confirmed Speakers Include:




Emeran Mayer

Professor and Director, Center for Neurobiology of Stress, Division of Digestive Diseases, University of California, Los Angeles



Avi Spier

Director of Strategic Alliances, Novartis Institutes for BioMedical Research



E. Scott Stibitz

Chief, Laboratory of Enteric & Sexually Transmitted Diseases, CBER, U.S. FDA

Conference Synopsis

The Microbiome Community

- An overview of the human microbiome project
- Monitoring and regulating microbial communities
- Ethics, legal and social implications in microbiome research
- Diversity, stability and resilience of the microbiome
- Building a translation microbiome program
- Can we characterise the 'normal' microbiome?
- The human virome & its applications in health and disease
- Sequencing and bioinformatics of the human microbiome
- Bioinformatics and large data management, data storage and how we use the data we have collected
- Metagenomic and post-metagenomic approaches to microbiome research

Venture Capital, Collaboration, Investment and Commercialisation

- Venture capital investment opportunities
- Commercialising the microbiome: Developing business relationships between academic research, pharma and business ventures
- Collaboration partnerships – the global scope of microbiome research/structuring successful collaborations
- Bringing live microbial products to market – IP and regulation
- Pharmaceutical involvement and investment
- Small company showcase

The Human Microbiome in Health and Disease

- Antibiotic Exposure: Contemplating novel antibiotic therapies that do not destroy the healthy microbiome
- Case studies: The microbiome and its role in IBD, cancer, obesity, immunity, diabetes and cancer
- Studies in the GI tract & intestinal epithelium
- Microbiome transplantation/fecal transplantation
- Examining bacteriophage therapy for patients worldwide

Research and Development outside the Gut

- How does age affect the microbiome – young and elderly microbiome
- Skin microbiome – acne, eczema, atopic dermatitis, probiotics, wound health
- Microbiome and cosmetic applications
- Oral microbiome and vaginal microbiome in health and disease
- Commercialising therapies for respiratory disease from lung microbiome research
- Latest developments on gut-brain axis and behaviour

Microbiome and the Food World

- Developing nutritional products utilising microbiome research
- Can disease be controlled via diet
- Probiotics, prebiotics and pharmaceuticals
- Probiotics and the public – mobilising dietary supplements within economic markets

For more information please contact Steve Hambrook, Conference Director, Global Engage Ltd.

steve@globalengage.co.uk

+44 (0) 1865 849841


Confirmed Speakers



Yvonne Huang
Assistant Professor; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor




David Underhill
Professor, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center



Delphine Lee
Director, Dirks/Dougherty Laboratory for Cancer Research Director, Dept. of Translational Immunology, John Wayne Cancer Institute at Providence SJHC



Glenn Marrichi
Chief Executive Officer, BiomeSapien




Arpita Maiti
Director, External R&D Innovation, Inflammation and Immunology, Pfizer




Joseph Larkin III
Assistant Professor, Department of Microbiology and Cell Science, University of Florida



Eric de la Fortelle
Venture Partner, Seventure Partners



Dirk Gevers
Global Head, Janssen Human Microbiome Institute, Janssen Research & Development [RESERVED]



Susanne Szabo
Director of Immunology and Ecobiotic Screening, Seres Therapeutics, Inc.



Jackie Papkoff
Vice President Immunology Scientific Innovation, Johnson & Johnson California Innovation Center



Michael Step
Chief Executive Officer, Ritter Pharmaceuticals




Emeran Mayer
Professor and Director, Center for Neurobiology of Stress, Division of Digestive Diseases, University of California, Los Angeles



Derrick MacFabe
Director, The Kilee Patchell-Evans Autism Research Group, University of Western Ontario, Canada



Joseph Petrosino
Director, Alkek Center for Metagenomics & Microbiome Research, Baylor College of Medicine



E. Scott Stibitz
Chief, Laboratory of Enteric and Sexually Transmitted Diseases, CBER, U.S. Food and Drug Administration



Amelia Laouar
Assistant Professor of Surgery, Child Health Institute of New Jersey, Rutgers State University



Nigel Beeley
R&D Consultant, Elcelyx Therapeutics and Nazura BioHealth Inc.



Avi Spier
Director of Strategic Alliances, Novartis Institutes for BioMedical Research



Harro Timmerman
Principal Scientist Microbiota in Health & Disease, NIZO Food Research BV, The Netherlands



Pierre Belichard
Chief Executive Officer, Enterome Biosciences



Yuli Song
Senior Scientist, Oral Care R&D, P&G



Alexander Vlassov
Senior Staff Scientist, Thermo Fisher Scientific



Steven Gill
Associate Professor - Department of Biology & Director, Genomics Research Center, University of Rochester



Karen Madsen
Professor of Medicine & Co-director of the "Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)", University of Alberta, Canada



Felix Frueh
Chief Scientific Officer, Human Longevity Inc.



Bernat Olle
Co-Founder & Chief Operating Officer, Vedanta Biosciences & Venture Partner, PureTech Ventures



Temitope Keku
Professor of Medicine, University of North Carolina, Chapel Hill




Eric Huang
Professor of Dermatology, University of California, San Diego



Julia Oh
Assistant Professor, Jackson Laboratory for Genomic Medicine



Malcolm Kendall
Co-Founder & Chief Executive Officer, Microbiome Insights Inc.



Senior Representative
4D Pharma plc.



Thomas Schmidt
Professor, Department of Internal Medicine, University of Michigan



Amanda Ramer-Tait
Assistant Professor, Food Science and Technology, University of Nebraska - Lincoln

Also Speaking:

Richard McCallum, Professor of Medicine and Founding Chair, Department of Internal Medicine, Texas Tech University [Session Chair]

Senior Representative, CryoXtract

Carlos Merino, Busines & Technology Leaders , DNA Genotek

Christopher Taylor, Associate Professor, Microbiology, Immunology & Parasitology LSU Health Sciences Center New Orleans [Session Chair]

Joe Sliman, Senior Vice President, Clinical & Regulatory, Synthetic Biologics

Eric Harvill, Professor of Microbiology and Infectious Disease, Penn State University [Session Chair]

Senior Representative, Synco Bio Partners

Lada Rasochova, CEO, Dermalma Inc.

For more information please contact Steve Hambrook, Conference Director, Global Engage Ltd.

steve@globalengage.co.uk

+44 (0) 1865 849841

Sponsors 2015

Platinum Sponsor:



Gold Sponsor:



Gold Sponsor:



Silver Sponsor:



Silver Sponsor:



Silver Sponsor:



Other Sponsors



Venue

San Diego Marriott Mission Valley
8757 Rio San Diego Drive
San Diego, CA
92108

A discounted group rate will be available to all attendees. Details of how to book are available on registration. Space is limited and accommodation is available on a first come basis.



For more information please contact Steve Hambrook, Conference Director, Global Engage Ltd.

steve@globalengage.co.uk

+44 (0) 1865 849841

Agenda: Day One – Thursday 10th September 2015

08.00-08.40	Registration & Coffee [Location: Pavilion]	
08.40-08.50	Global Engage Welcome Address & Morning Chair's Opening Remarks [Location: Rio Vista Ballroom Salons A-D]	
	Morning Chair & Session Sponsor: Pierre Belichard, CEO, Enterome Biosciences	
08.50-09.20	Keynote Address: Title To Be Confirmed Regulation of Microbiome Therapeutics CONFIRMED: E. Scott Stibitz, Chief, Laboratory of Enteric and Sexually Transmitted Diseases, CBER, U.S. Food and Drug Administration	
09.20-09.45	Title To Be Confirmed CONFIRMED: Joseph Petrosino, Director, Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine	
09.45-10.15	Solution Provider Presentation: Title To Be Confirmed CONFIRMED: Senior Representative, 4D Pharma plc.	Platinum Sponsor: 
10.15-11.25	Morning Refreshments [Location: Pavilion] Poster Presentations & Networking Meetings Gut Microbiome in Health & Disease	
11.25-11.50	Fecal Transplantation in the Treatment of Inflammatory Bowel Disease - Clinical results to date - Mechanisms related to success and failure - Future directions CONFIRMED: Karen Madsen, Professor of Medicine & Co-director of the "Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)", University of Alberta, Canada	
11.50-12.15	The Intestinal Microbiota and Colorectal Cancer The human gut is home to a complex microbiota that is important to the intestinal homeostasis of the host. Colorectal cancer is a complex disease influenced by environmental, dietary and microbial factors. Alterations in the composition of the intestinal microbiota have been implicated in colorectal adenomas and cancer. However, most studies have largely focused on "Who is there?" and it is not yet clear whether shifts in the microbiota are a cause or consequence of colorectal cancer. Functional and mechanistic studies are needed to provide insights into how the microbiota or microbial products initiate and promote carcinogenesis. I will discuss results from our studies as well as others to provide evidence that shifts in microbial communities or specific microbes promote or protect against colorectal adenomas and cancer. Other questions that will be addressed are: are there microbial signatures or metabolites that can be used to predict colorectal cancer risk? What is the functional implicational implications of gut bacterial dysbiosis relative to colorectal cancer? CONFIRMED: Temitope Keku, Professor of Medicine, University of North Carolina, Chapel Hill	
12.15-12.40	Fungal Microbiomes in Health and Disease - Describe the composition of fungal communities in different anatomical sites - Describe current research on the role of the mycobiome in health and disease states - Describe technical challenges in assessing fungal communities CONFIRMED: David Underhill, Professor, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center	
12.40-13.10	Solution Provider Presentation: Title To Be Confirmed CONFIRMED: Pierre Belichard, CEO, Enterome Biosciences, France	Silver Sponsor: 
13.10-14.10	Lunch [Location: Pavilion] Session Chair: Richard McCallum, Professor of Medicine and Founding Chair, Department of Internal Medicine, Texas Tech University	
14.10-14.40	Solution Provider Presentation: Title To Be Confirmed CONFIRMED: Joe Sliman, Senior Vice President, Clinical & Regulatory, Synthetic Biologics	
14.40-15.05	Title To Be Confirmed CONFIRMED: Arpita Maiti, Director, External R&D Innovation, Inflammation and Immunology, Pfizer	

For more information please contact Steve Hambrook, Conference Director, Global Engage Ltd.

steve@globalengage.co.uk

+44 (0) 1865 849841

15.05-16.05	Panel Discussion: Venture Capital and Microbiome Investment - Current market opportunities - Evaluating the funding climate - Perspective on building revenue models for the industry CONFIRMED: Chair: Malcolm Kendall, Co-Founder & CEO, Microbiome Insights Inc. Bernat Olle, Co-Founder & Chief Operating Officer, Vedanta Biosciences & Venture Partner, PureTech Ventures Eric de la Fortelle, Venture Partner, Seventure Partners Nigel Beeley, R&D Consultant, Elcelyx Therapeutics, Inc. and Nazura BioHealth, Inc. Michael Step, Chief Executive Officer, Ritter Pharmaceuticals	
16.05-16.30	Developing Relationships between Academic Research and Business Ventures - Commercializing the microbiome requires the transformation of advanced academic research into promising business ventures. The healthcare sea change in the U.S. in the wake of the Affordable Care Act has demonstrated that aligning quality outcomes while driving cost efficiencies is paramount. - Large companies are seeking to ally their R&D interests with academic research teams capable of accelerating microbiome discovery and product development. - Alignment with experienced companies early in the development process can smooth the pathway to funding, regulatory acceptance, commercialization and marketplace success. CONFIRMED: Glenn Marrichi, CEO, BiomeSapien [and] Thomas Schmidt, Professor, Department of Internal Medicine, University of Michigan	
16.30-17.20	Afternoon Refreshments [Location: Pavilion] Poster Presentations & Networking Meetings Short Presentation Showcase A series of short presentations from companies looking to commercialise microbiome research, the science behind their findings and the innovation and partnerships they are bringing to microbiome research. Session Chair:	
17.20-17.35	Impact of RP-G28 on the Human Microbiome and Treating the Symptoms of Lactose Intolerance - One of most advanced therapeutics in microbiome research and development. - RP-G28 is a complex dietary food that modulates the gut microbiome by stimulating growth of beneficial colonic bacteria - Developing the first Rx Treatment for Lactose Intolerance CONFIRMED: Michael Step, Chief Executive Officer, Ritter Pharmaceuticals	
17.35-17.50	The Complete Workflow Solution for Microbiome Research The presentation will describe the workflows and latest tools for human microbiome research, including: (1) sample collection; (2) storage; (3) isolation of microbial DNA; (4) initial DNA analysis by NanoDrop™ spectrophotometer, Qubit® fluorometer, and agarose gel electrophoresis; (5) qPCR with TaqMan® assays and next gen sequencing. CONFIRMED: Alexander Vlassov, Senior Staff Scientist, Thermo Fisher Scientific	
17.50-18.05	Title To Be Confirmed CONFIRMED: Senior Representative, SynCo Bio Partners	
18.05-18.20	Title To Be Confirmed CONFIRMED: Senior Representative, DNA Genotek	
18.20-18.35	Title To Be Confirmed CONFIRMED: Senior Representative, CryoXtract	
18.20	Chairman's Closing Remarks & End of Day One	
18.20-19.20	Drink's Reception [Location: Pavilion]	

Coffee & Stream Chair's Opening Address [Location: Rio Vista Ballroom Salons A-D]

Session Chair: Christopher Taylor, Associate Professor, Microbiology, Immunology & Parasitology LSU Health Sciences Center New Orleans

08.40-09.10 Keynote Address:

The Gut Microbiome and its Impact on the Human Gut-Brain Axis

Tremendous progress has been made in recent years to characterize the bi-directional interactions between the central nervous system, the enteric nervous system and the gastro-intestinal tract. Based on a series of provocative pre-clinical studies it has become evident that the gut microbiome plays a prominent role in these bidirectional interactions. Limited information is available to suggest how these preclinical findings translate to healthy humans, or to disease states involving the brain, or the brain gut axis. This limited information comes from studies demonstrating associations between altered microbial composition and metabolites and disease states involving the brain gut axis (including irritable bowel syndrome, colicky babies), as well as studies demonstrating brain changes in response to alterations of the gut microbiota with probiotics. It remains to be determined if gut microbial influences play an important role during human brain development and to what degree they can influence the function of the adult brain and associated behaviors. This presentation will assess what's been learned so far and where next steps might take us.

CONFIRMED:

Emeran Mayer, Professor and Director, Center for Neurobiology of Stress, Division of Digestive Diseases, UCLA

09.10-09.35 **Enteric Short Chain Fatty Acids: Microbial Messengers of Metabolism, Mitochondria and Mind: Implications in Autism Spectrum Disorders**

Clinical observations suggest that gut and dietary factors, transiently worsen, and in some cases appear to improve, behavioral symptoms in autism spectrum disorders (ASDs), but the reason of this is unclear. Recent evidence suggests ASD as a family of systemic disorders of increasing incidence manifesting altered immunity, metabolism and gene expression, and altered components of the gut microbiome. Pre or perinatal infection or hospitalization is emerging as a major risk factor for ASD. Can a common environmental agent link these disparate findings? Basic science and clinical evidence supports that enteric short chain fatty acids, present in diet and produced by the gut microbiome, particularly by opportunistic gut bacteria following carbohydrate ingestion, may be key triggers in ASD. Administration of propionic acid, a major fermentation product associated with ASD associated gastrointestinal bacteria, in rodents elicits behavioral, electrographic, neuroinflammatory, metabolic (lipid, mitochondrial, redox) and epigenetic changes closely resembling those found in ASDs. We hypothesize that ASDs are produced by pre or post-natal antibiotic resistant bacterial infections in sensitive sub populations, which may have major implications in ASD cause, diagnosis and treatment. Collectively, this offers further support that gut microbiome metabolites, such as dietary or enteric bacterially produced short chain fatty acids, 1) are underappreciated modulators of brain development and behavior 2) may be plausible environmental agents that can trigger or exacerbate ASDs and 3) deserve further exploration in basic science, agriculture, and clinical medicine.

CONFIRMED:

Derrick MacFabe, Assistant Professor and Director, The Kilee Patchell-Evans Autism Research Group, University of Western Ontario, Canada

09.35-10.05

Solution Provider Presentation

For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk

10.05-10.10

Gut Microbiome
[Location: Rio Vista Ballroom Salons A-D]

Skin Microbiome & Dermatology
[Location: Cabrillo Ballroom Salons 1-2]

Session Chair: Christopher Taylor, Associate Professor, Microbiology, Immunology & Parasitology LSU Health Sciences Center New Orleans

Session Chair: Lada Rasochova, CEO, Dermala Inc.

10.10-10.35

Gut Microbiota Induces Intestinal Immune Cells with SLAMF4 which Provides Protection against Enteric Infection

The expression of SLAMF4, an innate receptor, is limited to NK cell types and some CD8+ T cells. Here we report that SLAMF4 is expressed on almost all hematopoietic CD45+ cells in the intestinal mucosa (>70%). In contrast, SLAMF4+ cells were detected only on minor immune cell populations in other body's organs (< 5%). In concordance with the murine data, SLAMF4 was also found to be expressed at high levels in human small intestine and colon. By using UBC-GFP bone marrow chimera and lymphotoxin- α deficient mice, we revealed that SLAMF4 imprinting on gut hematopoietic-derived cells occurs directly in the gut mucosa and independent of the gut-associated lymphoid tissue (GALT). Interestingly, SLAMF4-expressing cells largely disappeared in germ-free (GF) and antibiotics treated mice, indicating a critical role of gut microbiota. In "conventionalized" GF-mice, SLAMF4 expression in the intestinal mucosa reappeared, an outcome that exemplifies host-microbe communication within the intestine. Importantly, we show that SLAMF4 positively regulates intestinal immunity and promotes protection against *Listeria monocytogenes*. Our work thus identifies SLAMF4 as a tissue-specific immunomodulatory receptor, whose expression in intestinal immune cells is dependent on the continued presence of gut microbiota and promotes protective functions against enteric pathogens.

CONFIRMED:

Amelia Laouar, Assistant Professor of Surgery, Child Health Institute of New Jersey, Rutgers State University

Probiotic Bacteria in the Human Skin Microbiome Against Dysbiotic Acne Vulgaris

Mounting evidence indicates that the commensal microbes in the human microbiome can employ microbial interference to protect hosts from foreign pathogens. However, comparatively little is known about how commensal microbes regulate their internal environment to achieve homeostasis when one of microbes grows out of control. Results in our publication indicate that *Staphylococcus epidermidis* (*S. epidermidis*), a skin commensal bacterium, can exploit carbohydrate fermentation to hold back the over-growth of opportunistic *Propionibacterium acnes* (*P. acnes*). Our findings define the probiotic function of skin microbiome as part of skin immunity for controlling the dysbiosis, a deficiency of good bacteria and/or an over-growth of harmful organisms. Isotretinoin derived from vitamin A is a powerful and effective medication for acne treatments. However, it is strictly regulated due to the induction of serious side effects. Many antibiotics have been used for treatments of acne vulgaris, but these antibiotics are non-specific and have a risk of creating antibiotic-resistant bacteria. We here introduce a new concept that skin bacteria express bacterial interference via fermentation to keep the skin microbiome balanced for optimal skin health. Inappropriate use of antibiotics may disrupt the homeostasis of skin microbiome, destroying natural and self-curative of human body. The carbohydrate fermentation of *S. epidermidis* produced detectable short-chain fatty acids (SCFAs), primarily butyric, acetic, and succinic acids, and significantly interfered with the growth of *P. acnes* in vitro, in vivo and in human acne explants. The novel acne treatment using skin probiotic by specific induction of *S. epidermidis* fermentation within an acne microenvironment may benefit the entire community of patients with acne vulgaris consisting of over 50,000 patients in US.

CONFIRMED:

Eric Huang, Professor of Dermatology, University of California, San Diego

10.35-11.45

Morning Refreshments & Networking Meetings [Location: Pavilion]

For more information please contact Steve Hambrook, Conference Director, Global Engage Ltd.

steve@globalengage.co.uk

+44 (0) 1865 849841

11.45-12.10	Dietary Fibers, the Gut Microbiome and Metabolic Health Dietary fiber, whole grains, and other indigestible but fermentable carbohydrates such as resistant starches (RS) have been studied extensively as promising nutritional interventions for preventing obesity and modulating insulin sensitivity. Although these benefits likely arise from a multitude of mechanisms, the gut microbiota is increasingly considered one of the key factors underlying these health benefits. However, despite the rationale for considering the microbiota in mediating the physiological effects of RS and other fibers, most studies have only assessed bacterial participation by methods that do not make mechanistic links to specific taxa or functions. I will discuss findings from mouse experiments specifically designed to assess the contribution of the gut microbiota in mediating the health benefits of dietary fibers, including RS. CONFIRMED: Amanda Ramer-Tait, Assistant Professor, Food Science and Technology, University of Nebraska - Lincoln	The Host, Its Microbes, and Disease: The Landscape of the Human Skin Microbiome The human skin harbors an abundant microbial ecosystem with bidirectional metabolic exchanges supporting symbiotic and commensal functions. Sequence-based analysis of microbial community structure and organization of the human microbiome has yielded valuable insight into the microbial diversity and function of its different body niches. Metagenomic analyses of the diverse skin sites in healthy humans demonstrate that contrasting forces of the skin's biogeography and individual characteristics shape the skin microbiome and the dynamics of its bacteria, fungi, and viruses. However, shifts in the ecological properties of the skin microbiome are significantly associated with skin disease, disease severity, and other physiologic host factors such as age or primary immunodeficiency. Understanding the function, structure, and dynamics of the microbiome is important to design therapeutics that precisely target the pathogen of interest, yet spare the surrounding beneficial microbiota. CONFIRMED: Julia Oh, Assistant Professor, Jackson Laboratory for Genomic Medicine
12.10-12.35	Enhanced Antigen Presenting Cell Maturation by Resident Gut Bacteria Modulates T Lymphocyte Effector Functions in Mice Susceptible to Type 1 Diabetes Antigen presenting cells (APC) are critical in determining whether T lymphocytes, bearing TCR specificity to pancreas antigens, acquire diabetogenic effector functions. Although evidence implicates that APC are dysfunctional in autoimmune type 1 diabetes (T1D) patients and rodent models, it is unclear how resident gut flora can contribute to diabetogenic T cell maturation by APC. In this study, we observed that the T cell repertoire of spontaneously diabetic, non-obese diabetic (NOD) mice possessed a reduced Th17 bias in comparison to congenic non-obese resistant (NOR) mice, which are resistant to T1D. Notably, the distinctions in Th17 bias were correlated to reductions in peripheral APC and distinct microbial communities. Moreover, <i>Lactobacillus johnsonii</i> strain N6.2 (LjN6.2), shown to inhibit T1D and mediate a Th17 bias, enhanced maturation of dendritic cells. These data suggest that resident gut flora can modulate the T cell priming abilities of APC, thereby potentially inhibiting diabetogenic T cell maturation and T1D onset in individuals with genetic susceptibility to disease CONFIRMED: Joseph Larkin III, Assistant Professor, Department of Microbiology and Cell Science, University of Florida	Title To Be Confirmed Skin Microbiome in Ichthyosis vulgaris (genotype) and longitudinal Psoriasis CONFIRMED: Harro Timmerman, Principal Scientist Microbiota in Health & Disease, NIZO Food Research BV, The Netherlands
12.35-13.25	Panel Discussion: How to Foster the Growth of Microbiome Therapeutics • Review of where pharma is at with the microbiome • In-licensing and investment • Areas of focus and future development CONFIRMED: Chair: Avi Spier, Director of Strategic Alliances, Novartis Institutes for BioMedical Research Felix Frueh, Chief Scientific Officer, Human Longevity Inc. Arpita Maiti, Director, External R&D Innovation, Inflammation and Immunology, Pfizer Susanne Szabo, Director of Immunology and Ecobiotic Screening, Seres Therapeutics, Inc. Jackie Papkoff, Vice President Immunology Scientific Innovation, Johnson & Johnson California Innovation Center Reserved: Dirk Gevers, Global Head, Janssen Human Microbiome Institute, Janssen Research and Development	
13.25-14.25	Lunch [Location: Pavilion] Session Chair: Eric Harvill, Professor of Microbiology and Infectious Disease, Penn State University Session Chair: Lada Rasochova, CEO, Dermala Inc.	
14.25-14.55	Solution Provider Presentation For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk	Solution Provider Presentation For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk
14.55-15.20	Adoptive Transfer of Obese-type Gut Microbiota Induces Neurobehavioral Changes in Non-Obese Mice The influence of intestinal microbiota on the functioning of the brain, part of the so-called gut-brain axis, has become a well-studied phenomenon recently. There has also been renewed interest into the prevalence of mental illnesses, which are increased with obesity. We test the hypothesis that gut microbiota shaped by a high-fat diet are sufficient to induce neurobehavioral changes in mice in the absence of obesity. We perform an adoptive transfer of gut microbiota from mice maintained on a high-fat diet into non-obese mice that are maintained on a standard chow diet. We observe increased neuroinflammation and significant disruptions in cognitive and exploratory behavior in these mice when compared to a control group undergoing the same adoptive transfer procedure from chow-fed donor mice. CONFIRMED: Christopher Taylor, Associate Professor, Microbiology, Immunology & Parasitology LSU Health Sciences Center New Orleans	Microbes in the Breast A main focus of our group is to investigate microbes and the breast. Our published work and that of others suggests the breast tissue contains a bacterial microbiome and we are working on the physiologic relevance of this finding CONFIRMED: Delphine Lee, Director, Dirks/Dougherty Laboratory for Cancer Research & Director, Department of Translational Immunology, John Wayne Cancer Institute at Providence SJHC

15.20-15.45	Vaginal Microbiota of Post-Menopausal Women Vaginal microbiota undergoes major compositional changes throughout a women's lifespan and it appears that sex steroid hormones play major roles in driving the composition and stability of the vaginal microbiota. It has been well accepted that this highly dynamic yet well balanced microbial ecosystem plays an important role in reproductive age women's urogenital health. However, little is known about its composition and function in postmenopausal population. With emerging new product forms, new technologies and new benefit areas targeting this unique consumer populations, there is an increased need to understand the vaginal microbiota and its role in women's health in this particular population. This presentation includes what we have learned about vaginal microbiota and what the implications are and some questions raised that need to be discussed. CONFIRMED: Yuli Song, Senior Scientist, Oral Care R&D, P&G	Title To Be Confirmed Reserved:
15.45-16.00	Small Company Showcase For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk	Small Company Showcase For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk
16.00-16.30	Afternoon Refreshments [Location: Pavilion]	
16.30-16.55	Emerging Roles of the Oral Cancer Microbiome in Anti-Tumor Immunity Oral squamous cell carcinoma (OSCC) is one of the top ten cancers worldwide and a multicausal disease, influenced by consumption of tobacco and alcohol, HPV infection and microbiota associated oral inflammatory diseases. Genomic analysis OSCC intratumoral microbiota has revealed dysbiosis and increased abundance of oral pathogens as oral premalignant lesions undergo malignant transformation. In this presentation, I summarize our current work, in which we address the role of the OSCC intratumoral microbiome on tumor-associated immune function. We use RNA-Seq and flow cytometry to characterize the intratumoral transcriptome and the immune cell populations with a focus on two questions: 1) does the microbiota alter the immunosuppressive (or immunostimulatory) nature of the tumor microenvironment and 2) does the microbiota dictate which immune cells infiltrate into the tumor. CONFIRMED: Steven Gill, Associate Professor - Department of Biology & Director, Genomics Research Center, University of Rochester	
16.55-17.20	Asthma and the Airway Microbiome: New Insights and Hypotheses • Discuss results of recent airway microbiome investigations in asthma. • Synthesize how insights from asthma microbiome studies inform new research directions on asthma. • Discuss implications of the above for asthma treatments or management. CONFIRMED: Yvonne Huang, Assistant Professor; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor	
17.20	Conference Close	



Microbiome Series Advisory Panel

Academic/Industry:

Sven Pettersson, Karolinska Institute, Sweden
Rochellys Diaz Heijtz, Karolinska Institute, Sweden
Dennis Sandris Nielsen, University of Copenhagen, Denmark
Victor Nizet, UCSD, USA
Huiying Li, UCLA, USA
Kim Capone, Johnson & Johnson, USA
Sunny Wong, Chinese University of Hong Kong
Deshanie Rai, Bayer Healthcare, USA

Eric Harvill, Penn State University, USA
Elisabeth Norin, Karolinska Institute, Sweden
Ailsa Hart, St. Mark's Hospital, UK
Roopal Thakkar, AbbVie, USA
Georgios Stamatas, Johnson & Johnson, France
Martha Clokier, University of Leicester, UK
Jos van Strijp, Utrecht University Medical Center, The Netherlands
Tom van de Wiele, Ghent University, Belgium
Jane Muir, Monash University, Australia

Hiroshi Ohno, RIKEN, Japan
Karen Scott, Rowett Institute, UK
GwangPyo Ko, Seoul National University, Korea
Mani Arumugam, University of Copenhagen, Denmark
Jen Fettweis, VCU, USA
Jackie Papkoff, Johnson & Johnson, USA
Andrea Azcarate-Peril, University of North Carolina, USA

Investment/Partnering:

Nigel Beeley, R&D Consultant

How To Register

Phone:

+44 (0) 1865 849841

Fax:

+44 (0) 1865 598989

Email:

info@globalengage.co.uk

Web:

www.globalengage.co.uk/microbiome.html

Mail:

Global Engage,
Suite B, The Kidlington Centre,
Kidlington, Oxfordshire, OX5 2DL
United Kingdom

QR:



Delegate	One	Two	Three (this place is free)
Mr, Mrs, Ms, Dr, Prof:			
First Name			
Family Name			
Position			
Email			

Contact

Organization

Address

Cell:

Tel:

Email:

Conference Fees

Industry Delegate	\$1295	Discount Code:
Academic Delegate	\$795	Discount Code:

Payment Details

Total: \$

Cheques should be made out to: Global Engage Ltd.

☐ Please tick here to receive an invoice in advance of payment

Bank transfer *

IBAN: GB39MIDL 40051573047458 BIC: MIDLGB22

Credit Card: ☐ VISA ☐ AMEX+ ☐ MASTERCARD

Card No:

3 or 4 digit security code:

Expiry Date:

VENUE
San Diego Marriott Mission Valley
8757 Rio San Diego Drive
San Diego, CA
92108

CONFIRMATION:
If you have not received confirmation of your booking prior to the event, please call Global Engage on +44 (0) 1865 849841. Your delegate place is not confirmed until payment is acknowledged. Payment must be received before the conference date. If payment has not been received before the conference date Global Engage reserves the right to ask for a credit or debit card guarantee of payment when you arrive at the conference venue.

ORDER CONFERENCE DOCUMENTATION:
I cannot attend the conference but wish to buy the event documentation pack, which includes the speakers presentations
Full documentation costs \$199.
☐

ACCOMMODATION:
Hotel accommodation is not included in your fee. To reserve a room at the conference hotel, please send an email to Scott Taylor at scott@globalengage.co.uk.

***BANK TRANSFER PAYMENTS:**
When paying by Bank Transfers quote this reference: MBF (Please ensure ALL bank charges are met by your organisation)

PROGRAMME CHANGES:
Global Engage reserves the right to make any necessary alterations/changes to the programme.
Personal Data is gathered in accordance with the Data Protection Act 1998.
If you do not wish to receive promotional material from Global Engage, please tick here ☐
If you do not wish to receive promotional material from the Event Sponsors, please tick here ☐
If you do not wish to receive promotional material from any other 3rd party, please tick here ☐

OTHER DETAILS:
Full Terms & Conditions are set out at
www.globalengage.co.uk/terms.html

+AMEX PAYMENTS
We can accept payment by Amex, but there is a 2% surcharge to cover their charges. Amex transactions will be processed in GBP at the rate of the day so the final amount charged may vary slightly from the actual fee above.

CANCELLATIONS/SUBSTITUTIONS:
Delegates cancelling more than one calendar month prior to event receive a full refund, one calendar month or less prior to event there is no refund. A substitute delegate of equal standing can be nominated within a week of the event and must be approved by the Organiser in advance in order to avoid cancellation charges.

THE DELEGATE BOOKING FEE INCLUDES:
All meals and refreshments throughout the conference day, conference presentations, open workshop and general panel sessions and networking/social events, conference and speaker notes.

MONEY BACK GUARANTEE:
Book now and if your plans change, you can get a 100% refund right up to the 10th August 2015.

To order, complete the registration form and method of payment. Payment must be received before the documentation and password can be despatched.

Please return this form with the address and customer code, clearly visible if you wish us to remove your records from our database.